| Resistin is expressed in human macrophages and directly regulated by PPARγ activators L Patel, AC Buckels, IJ Kinghorn, PR Murdock, JD Holbrook, C Plumpton, ... Biochemical and biophysical research communications 300 (2), 472-476, 2003 | 1379 | 2003 |
| Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease CJ Packard, DSJ O'Reilly, MJ Caslake, AD McMahon, I Ford, J Cooney, ... New England Journal of Medicine 343 (16), 1148-1155, 2000 | 1202 | 2000 |
| Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target A Zalewski, C Macphee Arteriosclerosis, thrombosis, and vascular biology 25 (5), 923-931, 2005 | 723 | 2005 |
| Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo SU Naik, X Wang, JS Da Silva, M Jaye, CH Macphee, MP Reilly, ... Circulation 113 (1), 90-97, 2006 | 488 | 2006 |
| Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN L Patel, I Pass, P Coxon, CP Downes, SA Smith, CH Macphee Current Biology 11 (10), 764-768, 2001 | 487 | 2001 |
| Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a … CH MACPHEE, KE MOORES, HF BOYD, D DHANAK, RJ IFE, CA LEACH, ... Biochemical Journal 338 (2), 479-487, 1999 | 465 | 1999 |
| Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development RL Wilensky, YI Shi, ER Mohler III, D Hamamdzic, ME Burgert, J Li, ... Nature medicine 14 (10), 1059-1066, 2008 | 446 | 2008 |
| Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease MJ Caslake, CJ Packard, KE Suckling, SD Holmes, P Chamberlain, ... Atherosclerosis 150 (2), 413-419, 2000 | 422 | 2000 |
| Lipoprotein-Associated Phospholipase A2, Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions T Häkkinen, JS Luoma, MO Hiltunen, CH Macphee, KJ Milliner, L Patel, ... Arteriosclerosis, thrombosis, and vascular biology 19 (12), 2909-2917, 1999 | 367 | 1999 |
| The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages H Vosper, L Patel, TL Graham, GA Khoudoli, A Hill, CH Macphee, I Pinto, ... Journal of Biological Chemistry 276 (47), 44258-44265, 2001 | 364 | 2001 |
| myo‐Inositol metabolites as cellular signals CP Downes, CH Macphee European Journal of Biochemistry 193 (1), 1-18, 1990 | 273 | 1990 |
| Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins DG Tew, C Southan, SQJ Rice, GMP Lawrence, H Li, HF Boyd, K Moores, ... Arteriosclerosis, thrombosis, and vascular biology 16 (4), 591-599, 1996 | 230 | 1996 |
| Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils JR White, C Imburgia, E Dul, E Appelbaum, K O'Donnell, DJ O'Shannessy, ... Journal of leukocyte biology 62 (5), 667-675, 1997 | 210 | 1997 |
| Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses Y Shi, P Zhang, LF Zhang, H Osman, ER Mohler III, C Macphee, ... Atherosclerosis 191 (1), 54-62, 2007 | 203 | 2007 |
| Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. CH Macphee, DH Reifsnyder, TA Moore, KM Lerea, JA Beavo Journal of Biological Chemistry 263 (21), 10353-10358, 1988 | 185 | 1988 |
| Lipoprotein-associated phospholipase A2 and atherosclerosis RL Wilensky, CH Macphee Current opinion in lipidology 20 (5), 415-420, 2009 | 164 | 2009 |
| Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages KLH Carpenter, IF Dennis, IR Challis, DP Osborn, CH Macphee, ... FEBS letters 505 (3), 357-363, 2001 | 162 | 2001 |
| The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2 JA Blackie, JC Bloomer, MJB Brown, HY Cheng, B Hammond, ... Bioorganic & medicinal chemistry letters 13 (6), 1067-1070, 2003 | 158 | 2003 |
| Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib NK Acharya, EC Levin, PM Clifford, M Han, R Tourtellotte, D Chamberlain, ... Journal of Alzheimer's Disease 35 (1), 179-198, 2013 | 154 | 2013 |
| Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target CH Macphee Current opinion in pharmacology 1 (2), 121-125, 2001 | 150 | 2001 |
